Company overview
PGxAI provides an AI-powered pharmacogenomics platform that delivers personalized drug selection, dosage recommendations, and interaction predictions using machine learning and real-world data. It supports biopharmaceutical sponsors, CROs, and healthcare providers by optimizing clinical trial design, reducing adverse drug reactions, and generating pharmacogenomic reports covering over 730 drugs and 40 genes. The platform integrates generative models, LLMs, and partnerships like Sequencing.com and Novo Genomics to enhance precision medicine.
Pgxai is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include pharmacogenomics, ai precision medicine, drug-gene interactions, clinical trial ai, personalized dosing.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://pgx.ai
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- pharmacogenomics, ai precision medicine, drug-gene interactions, clinical trial ai, personalized dosing
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What capabilities does PGxAI offer for clinical trials?
- PGxAI empowers CROs and biopharmaceutical sponsors with PGx insights to identify optimal patient cohorts, predict drug-gene interactions, and optimize protocols, reducing trial failures and streamlining design.
- What is the coverage of PGxAI's pharmacogenomic reports?
- Reports cover over 730 drugs and 40 genes, providing personalized drug implications, up to five times the coverage of competitors, to reduce adverse reactions.
- In which geographies does PGxAI operate or partner?
- PGxAI, based in Palo Alto, partners with Sequencing.com for global reach and Novo Genomics to scale services across the Kingdom of Saudi Arabia (KSA).
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
